Actively Recruiting
Evaluation of JADE101 Given by Subcutaneous Injection in Adults With Immunoglobulin A Nephropathy Comparing Two Dosing Schedules and Placebo
Led by Jade Biosciences, Inc. · Updated on 2026-11-03
480
Participants Needed
4
Research Sites
65 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating JADE101, a drug administered by subcutaneous injection, for adults with immunoglobulin A nephropathy IgAN in this Phase 3 study. The trial compares the safety and effectiveness of JADE101 against a placebo to help better understand its impact on this kidney condition. The study is sponsored by Jade Biosciences, Inc. and aims to assess the drugs effect on protein levels in urine and kidney function. Participants will receive either JADE101 with maintenance doses every 8 weeks or every 12 weeks, or a placebo injection during the placebo-controlled treatment period. JADE101 and placebo are both given via subcutaneous injections. The study uses a randomized, double-blind design to fairly compare the groups, and treatment will continue for a specified period with regular dosing. During the trial, participants will have their urine protein creatinine ratio UPCR and estimated glomerular filtration rate eGFR measured at week 52 to evaluate kidney function and disease progression. Safety and efficacy will be monitored throughout the study, which is expected to last until September 2030. Participants must meet specific eligibility criteria including confirmed diagnosis, proteinuria levels, kidney function, and stable use of standard medications.
CONDITIONS
Brief Title
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Research Team
J
JADE101 Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here